Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621

Watchlist Manager
Beijing Sun-Novo Pharmaceutical Research Co Ltd Logo
Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Watchlist
Price: 66.65 CNY -1.77% Market Closed
Market Cap: ¥7.5B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Beijing Sun-Novo Pharmaceutical Research Co Ltd

There are no price targets for Beijing Sun-Novo Pharmaceutical Research Co Ltd.
Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
Not Available
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Beijing Sun-Novo Pharmaceutical Research Co Ltd Competitors:
Price Targets
G
SDA
Goldenbridge Acquisition Ltd
142% Upside
G
SDA
Goldenbridge Acquisition Ltd
142% Upside

Revenue
Forecast

36% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
36% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

For the last 5 years the compound annual growth rate for Beijing Sun-Novo Pharmaceutical Research Co Ltd's revenue is 36%. The projected CAGR for the next 3 years is 19%.

What are analyst estimates?

Operating Income
Forecast

28% / Year
Past Growth
129% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
28% / Year
Past Growth
129% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

For the last 5 years the compound annual growth rate for Beijing Sun-Novo Pharmaceutical Research Co Ltd's operating income is 28%. The projected CAGR for the next 1 year is 129%.

What are analyst estimates?

Net Income
Forecast

30% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
30% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

For the last 5 years the compound annual growth rate for Beijing Sun-Novo Pharmaceutical Research Co Ltd's net income is 30%. The projected CAGR for the next 3 years is 21%.

What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's stock price target?
Not Available

Beijing Sun-Novo Pharmaceutical Research Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Revenue forecast?
Projected CAGR
19%

For the last 5 years the compound annual growth rate for Beijing Sun-Novo Pharmaceutical Research Co Ltd's revenue is 36%. The projected CAGR for the next 3 years is 19%.

What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Operating Income forecast?
Projected CAGR
129%

For the last 5 years the compound annual growth rate for Beijing Sun-Novo Pharmaceutical Research Co Ltd's operating income is 28%. The projected CAGR for the next 1 year is 129%.

What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Net Income forecast?
Projected CAGR
21%

For the last 5 years the compound annual growth rate for Beijing Sun-Novo Pharmaceutical Research Co Ltd's net income is 30%. The projected CAGR for the next 3 years is 21%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 318,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.